We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a 14-0 vote yesterday, a Centers for Disease Control and Prevention (CDC) expert panel recommended the Pfizer/BioNTech COVID-19 vaccine for children age five to 11 years. Read More
The FDA is taking more time to review Moderna’s COVID-19 vaccine in adolescents age 12 to 17 years over concerns the messenger RNA (mRNA)-based shot may be associated with increased risk of myocarditis, a type of heart inflammation. Read More
The incidence of brain blood clots in one healthcare system increased by almost four times after introduction of the Johnson & Johnson (J&J) COVID-19 vaccine, according to data published in the Nov. 1 issue of the Journal of the American Medical Association. Read More
The FDA on Friday granted an updated Emergency Use Authorization (EUA) for the Pfizer/BioNTech COVID-19 vaccine for use in children ages five to 11 years — following a thumbs up from the agency’s expert advisory panel earlier in the week. Read More
A 10-day course of the inexpensive antidepressant fluvoaxamine cut the risk of COVID-19-related hospitalization by 32 percent in infected patients with comorbidities, a research team in Brazil has found. Read More
Merck has struck a licensing pact with the Medicines Patent Pool (MPP), a United Nations-supported public health organization serving the developing world, to expand access to its experimental COVID-19 antiviral pill, molnupiravir, co-developed with Ridgeback Biotherapeutics. Read More